David J. Inwards
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David J. Inwards has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Thomas E. Witzig
Division of Hematology Mayo Clinic Rochester Rochester Minnesota USA
4 shared publications - Ahmet Dogan
Division of Anatomic Pathology, Mayo Clinic, College of Medicine, Rochester, USA
2 shared publications - Angela Dispenzieri
Division of Hematology, Mayo Clinic, Rochester, USA
2 shared publications Anuradha Ananthamurthy
2 shared publications- Luis F. Porrata
Division of Hematology Mayo Clinic Rochester Minnesota USA
2 shared publications - Mark Robert Litzow
Mayo Clinic, Rochester, Minnesota, United States
2 shared publications
Latest Publications
- Open Access
- 10 January 2019
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 12 (1) , 6
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis
There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT. We evaluated 249 adult AITL patients who received their first allo-HCT during 2000–2016. The median patient age was 56 years (range = 21–77). Majority of the patients were Caucasians (86%), with a male predominance (60%). Graft-versus-host disease (GVHD) prophylaxis was predominantly calcineurin inhibitor-based approaches while the most common graft source was peripheral blood (97%). Median follow-up of survivors was 49 months (range = 4–170 months). The cumulative incidence of grade 2–4 and grade 3–4 acute GVHD at day 180 were 36% (95% CI = 30–42) and 12 (95% CI = 8–17), respectively. The cumulative incidence of chronic GVHD at 1 year was 49% (95%CI 43–56). The 1-year non-relapse mortality (NRM) was 19% (95% CI = 14–24), while the 4-year relapse/progression, progression-free survival (PFS), and overall survival (OS) were 21% (95% CI = 16–27), 49% (95% CI = 42–56), and 56% (95% CI = 49–63), respectively. On multivariate analysis, chemoresistant status at the time of allo-HCT was associated with a significantly higher risk for therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08–2.77), while KPS < 90% was associated with a significantly higher risk of mortality (inverse of OS) (RR = 3.46 95% CI = 1.75–6.87). Our analysis shows that allo-HCT provides durable disease control even in AITL patients who failed a prior auto-HCT and in those subjects with refractory disease at the time of allografting.
- 10 January 2019
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 12 (1) , 6
Open AccessAllogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis
There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT. We evaluated 249 adult AITL patients who received their first allo-HCT during 2000–2016. The median patient age was 56 years (range = 21–77). Majority of the patients were Caucasians (86%), with a male predominance (60%). Graft-versus-host disease (GVHD) prophylaxis was predominantly calcineurin inhibitor-based approaches while the most common graft source was peripheral blood (97%). Median follow-up of survivors was 49 months (range = 4–170 months). The cumulative incidence of grade 2–4 and grade 3–4 acute GVHD at day 180 were 36% (95% CI = 30–42) and 12 (95% CI = 8–17), respectively. The cumulative incidence of chronic GVHD at 1 year was 49% (95%CI 43–56). The 1-year non-relapse mortality (NRM) was 19% (95% CI = 14–24), while the 4-year relapse/progression, progression-free survival (PFS), and overall survival (OS) were 21% (95% CI = 16–27), 49% (95% CI = 42–56), and 56% (95% CI = 49–63), respectively. On multivariate analysis, chemoresistant status at the time of allo-HCT was associated with a significantly higher risk for therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08–2.77), while KPS < 90% was associated with a significantly higher risk of mortality (inverse of OS) (RR = 3.46 95% CI = 1.75–6.87). Our analysis shows that allo-HCT provides durable disease control even in AITL patients who failed a prior auto-HCT and in those subjects with refractory disease at the time of allografting.
- Open Access
- 23 July 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (10) , 2020-2024
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
We conducted this trial to determine the maximum tolerated dose (MTD) of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma. A standard phase I cohort of three study design was utilized. The fixed doses of rituximab and cladribine were 375 mg/m2 i.v. day 1 and 5 mg/m2/day i.v. days 1–5 of a 28-day cycle, respectively. There were five planned temsirolimus i.v. dose levels: 15 mg day 1; 25 mg day 1; 25 mg days 1 and 15; 25 mg days 1, 8 and 15; and 25 mg days 1, 8, 15, and 22. Seventeen patients were treated: three each at levels 1–4 and five at dose level 5. The median age was 75 years (52–86 years). Mantle Cell International Prognostic Index (MIPI) scores were low in 6% (1), intermediate in 59% (10), and high in 35% (6) of patients. Five patients were treated at level 5 without dose limiting toxicity. Hematologic toxicity was frequent: grade 3 anemia in 12%, grade 3 thrombocytopenia in 41%, grade 4 thrombocytopenia in 24%, grade 3 neutropenia in 6%, and grade 4 neutropenia in 18% of patients. The overall response rate (ORR) was 94% with 53% complete response and 41% partial response. The median progression-free survival was 18.7 months. Temsirolimus 25 mg i.v. weekly may be safely added to rituximab and cladribine at 375 mg/m2 i.v. day 1 and 5 mg/m2/day i.v. days 1–5 of a 28-day cycle, respectively. This regimen had promising preliminary activity in an elderly cohort of patients with mantle cell lymphoma. NCT00787969.
- 23 July 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (10) , 2020-2024
Open AccessPhase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
We conducted this trial to determine the maximum tolerated dose (MTD) of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma. A standard phase I cohort of three study design was utilized. The fixed doses of rituximab and cladribine were 375 mg/m2 i.v. day 1 and 5 mg/m2/day i.v. days 1–5 of a 28-day cycle, respectively. There were five planned temsirolimus i.v. dose levels: 15 mg day 1; 25 mg day 1; 25 mg days 1 and 15; 25 mg days 1, 8 and 15; and 25 mg days 1, 8, 15, and 22. Seventeen patients were treated: three each at levels 1–4 and five at dose level 5. The median age was 75 years (52–86 years). Mantle Cell International Prognostic Index (MIPI) scores were low in 6% (1), intermediate in 59% (10), and high in 35% (6) of patients. Five patients were treated at level 5 without dose limiting toxicity. Hematologic toxicity was frequent: grade 3 anemia in 12%, grade 3 thrombocytopenia in 41%, grade 4 thrombocytopenia in 24%, grade 3 neutropenia in 6%, and grade 4 neutropenia in 18% of patients. The overall response rate (ORR) was 94% with 53% complete response and 41% partial response. The median progression-free survival was 18.7 months. Temsirolimus 25 mg i.v. weekly may be safely added to rituximab and cladribine at 375 mg/m2 i.v. day 1 and 5 mg/m2/day i.v. days 1–5 of a 28-day cycle, respectively. This regimen had promising preliminary activity in an elderly cohort of patients with mantle cell lymphoma. NCT00787969.
- 1 July 2014
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 27 (3) , 242-245
Spontaneous Complete Remission of Angioimmunoblastic T-Cell Lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is a rare hematologic neoplasm that typically presents with B symptoms, anemia, and lymphadenopathy. Its overall prognosis is poor, with a 5-year survival rate of 30%. We present a case of AITL that went into spontaneous remission, an uncommon occurrence.
- 1 July 2014
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 27 (3) , 242-245
Spontaneous Complete Remission of Angioimmunoblastic T-Cell Lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is a rare hematologic neoplasm that typically presents with B symptoms, anemia, and lymphadenopathy. Its overall prognosis is poor, with a 5-year survival rate of 30%. We present a case of AITL that went into spontaneous remission, an uncommon occurrence.
- Open Access
- 22 July 2011
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 2 (6) , 381-392
Initial therapy of mantle cell lymphoma
Mantle cell lymphoma is a well-recognized distinct clinicopathologic subtype of B-cell non-Hodgkin lymphoma. The current World Health Organization (WHO) classification subdivides this entity into aggressive and other variants. The disease has a predilection for older males, and patients typically present at an advanced stage with frequent splenomegaly and extranodal involvement including bone marrow, peripheral blood, gastrointestinal, and occasional central nervous system involvement. Early studies of therapy outcomes in this disease revealed that while response rates where high, relapse was expected after a limited period of time. Prolonged survival was uncommon, with initial median survival rates typically in the 3–4-year range. Those with a high proliferative rate, blastoid morphology, and selected clinical features were recognized as having a worse prognosis. Therapeutic approaches have diverged into aggressive therapies with high response rates and promising progression free survival rates, which may be applied to younger healthy patients, and less aggressive approaches. Aggressive therapies include intensive chemotherapy alone or chemotherapy followed by autologous stem cell transplant, which has been shown to be most effective when applied in first remission. Whether these more intense therapies result in improved survival as compared with less aggressive therapies is not well established. Allogeneic transplant has also been investigated, although high treatment-related mortality and the risk of chronic graft versus host disease and the relatively advanced age of this patient population have tempered enthusiasm for this approach. A number of less aggressive therapies have been shown to produce promising results. Consolidation and maintenance strategies are an active area of investigation. A number of newer agents have shown promising activity in relapsed disease, and are being investigated in the front-line setting. Overall survival rates are improving in this disease, with current studies suggesting a median survival of 5 or more years.
- 22 July 2011
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 2 (6) , 381-392
Open AccessInitial therapy of mantle cell lymphoma
Mantle cell lymphoma is a well-recognized distinct clinicopathologic subtype of B-cell non-Hodgkin lymphoma. The current World Health Organization (WHO) classification subdivides this entity into aggressive and other variants. The disease has a predilection for older males, and patients typically present at an advanced stage with frequent splenomegaly and extranodal involvement including bone marrow, peripheral blood, gastrointestinal, and occasional central nervous system involvement. Early studies of therapy outcomes in this disease revealed that while response rates where high, relapse was expected after a limited period of time. Prolonged survival was uncommon, with initial median survival rates typically in the 3–4-year range. Those with a high proliferative rate, blastoid morphology, and selected clinical features were recognized as having a worse prognosis. Therapeutic approaches have diverged into aggressive therapies with high response rates and promising progression free survival rates, which may be applied to younger healthy patients, and less aggressive approaches. Aggressive therapies include intensive chemotherapy alone or chemotherapy followed by autologous stem cell transplant, which has been shown to be most effective when applied in first remission. Whether these more intense therapies result in improved survival as compared with less aggressive therapies is not well established. Allogeneic transplant has also been investigated, although high treatment-related mortality and the risk of chronic graft versus host disease and the relatively advanced age of this patient population have tempered enthusiasm for this approach. A number of less aggressive therapies have been shown to produce promising results. Consolidation and maintenance strategies are an active area of investigation. A number of newer agents have shown promising activity in relapsed disease, and are being investigated in the front-line setting. Overall survival rates are improving in this disease, with current studies suggesting a median survival of 5 or more years.
- Open Access
Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group
BACKGROUND.: The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL).METHODS.: Patients with MCL were treated on 2 sequential trials. In Trial 95‐80‐53, patients received 2‐CDA as initial therapy or at relapse. In Trial N0189, patients received combination 2‐CDA and rituximab as initial therapy. In both trials, 2‐CDA was administered at a dose of 5 mg/m2 intravenously on Days 1 through 5 every 4 weeks for 2 to 6 cycles, depending on response. In Trial N0189, rituximab 375 mg/m2 was administered on Day 1 of each cycle.RESULTS.: Results were reported for 80 patients. Twenty‐six previously untreated patients and 25 patients who had recurrent disease with a median age of 68 years received single‐agent 2‐CDA. The overall response rate (ORR) was 81% with 42% complete responses (CRs) in the previously untreated group. The median progression‐free survival (PFS) was 13.6 months (95% confidence interval [95% CI], 7.2‐22.1 months), and 81% of patients remained alive at 2 years. The ORR was 46% with a 21% CR rate in the recurrent disease group. The median PFS was 5.4 months (95% CI, 4.6‐13.1 months), and 36% of patients remained alive at 2 years. Twenty‐nine eligible patients with a median age of 70 years received 2‐CDA plus rituximab. The ORR was 66% (19 of 29 patient), and the CR rate was 52% (15 of 29 patients). The median duration of response for patients who achieved a CR had not been reached at the time of the current report, and only 3 of the patients who achieved a CR developed recurrent disease at a median follow‐up of 21.5 months.CONCLUSIONS.: 2‐CDA had substantial single‐agent activity in both recurrent and untreated MCL, and the results indicated that it may be administered safely to elderly patients. The addition of rituximab to 2‐CDA may increase the duration of response. Cancer 2008. © 2008 American Cancer Society.
Open AccessLong‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group
BACKGROUND.: The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL).METHODS.: Patients with MCL were treated on 2 sequential trials. In Trial 95‐80‐53, patients received 2‐CDA as initial therapy or at relapse. In Trial N0189, patients received combination 2‐CDA and rituximab as initial therapy. In both trials, 2‐CDA was administered at a dose of 5 mg/m2 intravenously on Days 1 through 5 every 4 weeks for 2 to 6 cycles, depending on response. In Trial N0189, rituximab 375 mg/m2 was administered on Day 1 of each cycle.RESULTS.: Results were reported for 80 patients. Twenty‐six previously untreated patients and 25 patients who had recurrent disease with a median age of 68 years received single‐agent 2‐CDA. The overall response rate (ORR) was 81% with 42% complete responses (CRs) in the previously untreated group. The median progression‐free survival (PFS) was 13.6 months (95% confidence interval [95% CI], 7.2‐22.1 months), and 81% of patients remained alive at 2 years. The ORR was 46% with a 21% CR rate in the recurrent disease group. The median PFS was 5.4 months (95% CI, 4.6‐13.1 months), and 36% of patients remained alive at 2 years. Twenty‐nine eligible patients with a median age of 70 years received 2‐CDA plus rituximab. The ORR was 66% (19 of 29 patient), and the CR rate was 52% (15 of 29 patients). The median duration of response for patients who achieved a CR had not been reached at the time of the current report, and only 3 of the patients who achieved a CR developed recurrent disease at a median follow‐up of 21.5 months.CONCLUSIONS.: 2‐CDA had substantial single‐agent activity in both recurrent and untreated MCL, and the results indicated that it may be administered safely to elderly patients. The addition of rituximab to 2‐CDA may increase the duration of response. Cancer 2008. © 2008 American Cancer Society.
- Open Access
- 15 February 2008
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (4) , 1105-1110
Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma
Purpose: B-lymphocyte stimulator and a proliferation-inducing ligand regulate B-cell homeostasis and immunoglobulin production and are overexpressed in B-cell malignancies. Atacicept (TACI-Ig), a recombinant fusion protein that inhibits both B-lymphocyte stimulator and a proliferation-inducing ligand, may be a novel treatment for B-cell malignancies. Experimental Design: A phase 1, open-label, dose-escalation study of atacicept in patients with relapsed or refractory B-cell lymphoma was done. Atacicept was given s.c. weekly for 5 weeks to sequential patient cohorts at doses of 2, 4, 7, or 10 mg/kg. Patients responding or with stable disease were eligible for treatment on an extension study for up to 24 weeks or until disease progression. Results: All patients were heavily pretreated (median number of previous treatments, 5; range, 1-10), and four patients had previously received a stem cell transplant. Four patients were treated at the 2, 4, or 7 mg/kg dose levels, and three patients received 10 mg/kg of atacicept. Atacicept was well tolerated at all doses. Three adverse events with grade 3 severity were reported for one patient, including jaw pain, gastrointestinal hemorrhage, and sepsis; all were considered unrelated to atacicept. Pharmacokinetic results were nonlinear, and treatment with atacicept resulted in dose-dependent decreases in immunoglobulin concentrations. Two patients had stable disease at 8 weeks, entered the extension study, and received additional doses of atacicept with no safety or tolerability concerns. Conclusion: Atacicept at doses of up to 10 mg/kg was well tolerated and showed biological activity by decreasing immunoglobulin concentrations, although tumor responses were not observed.
- 15 February 2008
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (4) , 1105-1110
Open AccessPhase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma
Purpose: B-lymphocyte stimulator and a proliferation-inducing ligand regulate B-cell homeostasis and immunoglobulin production and are overexpressed in B-cell malignancies. Atacicept (TACI-Ig), a recombinant fusion protein that inhibits both B-lymphocyte stimulator and a proliferation-inducing ligand, may be a novel treatment for B-cell malignancies. Experimental Design: A phase 1, open-label, dose-escalation study of atacicept in patients with relapsed or refractory B-cell lymphoma was done. Atacicept was given s.c. weekly for 5 weeks to sequential patient cohorts at doses of 2, 4, 7, or 10 mg/kg. Patients responding or with stable disease were eligible for treatment on an extension study for up to 24 weeks or until disease progression. Results: All patients were heavily pretreated (median number of previous treatments, 5; range, 1-10), and four patients had previously received a stem cell transplant. Four patients were treated at the 2, 4, or 7 mg/kg dose levels, and three patients received 10 mg/kg of atacicept. Atacicept was well tolerated at all doses. Three adverse events with grade 3 severity were reported for one patient, including jaw pain, gastrointestinal hemorrhage, and sepsis; all were considered unrelated to atacicept. Pharmacokinetic results were nonlinear, and treatment with atacicept resulted in dose-dependent decreases in immunoglobulin concentrations. Two patients had stable disease at 8 weeks, entered the extension study, and received additional doses of atacicept with no safety or tolerability concerns. Conclusion: Atacicept at doses of up to 10 mg/kg was well tolerated and showed biological activity by decreasing immunoglobulin concentrations, although tumor responses were not observed.
- 30 June 2007
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 82 (6) , 692-699
Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab
- 30 June 2007
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 82 (6) , 692-699
Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab
- 1 June 2007
- Vol. 82 (6) , 692-9
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.
- 1 June 2007
- Vol. 82 (6) , 692-9
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.
- 1 December 2006
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 19 (4) , 669-684
Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma
- 1 December 2006
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 19 (4) , 669-684
Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma
- Open Access
- 24 April 2006
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 37 (11) , 1017-1022
Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma
To evaluate autologous stem cell transplant (ASCT) in older patients with intermediate grade non-Hodgkin's lymphoma (NHL), the Mayo Clinic Rochester BMT database was reviewed for all patients 60 years of age and older who received ASCT for NHL between September 1995 and February 2003. Factors evaluated included treatment-related mortality (TRM), event-free survival (EFS) and overall survival (OS). Ninety-three patients were identified, including twenty-four (26%) over the age of 70 years. Treatment-related mortality (5.4%) was not significantly different when compared to a younger cohort (2.2%). At a median follow-up of 14 months (0.6–87.6 months), the estimated median survival is 25 months (95% confidence interval (CI) 12–38) in the older group compared to 56 months (95% CI 37–75) (P=0.037) in the younger group. The estimated 4-year EFS was 38% for the older group compared to 42% in the younger cohort (P=0.1). By multivariate analysis, the only factor found to influence survival in the older group was age-adjusted International Prognostic Index at relapse, 0–1 better than 2–3 (P=0.03). Autologous stem-cell transplant can be safely performed in patients 60 years or older with chemotherapy sensitive relapsed or first partial remission NHL. The outcome may not be different from that of younger patients in terms of TRM and EFS.
- 24 April 2006
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 37 (11) , 1017-1022
Open AccessAutologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma
To evaluate autologous stem cell transplant (ASCT) in older patients with intermediate grade non-Hodgkin's lymphoma (NHL), the Mayo Clinic Rochester BMT database was reviewed for all patients 60 years of age and older who received ASCT for NHL between September 1995 and February 2003. Factors evaluated included treatment-related mortality (TRM), event-free survival (EFS) and overall survival (OS). Ninety-three patients were identified, including twenty-four (26%) over the age of 70 years. Treatment-related mortality (5.4%) was not significantly different when compared to a younger cohort (2.2%). At a median follow-up of 14 months (0.6–87.6 months), the estimated median survival is 25 months (95% confidence interval (CI) 12–38) in the older group compared to 56 months (95% CI 37–75) (P=0.037) in the younger group. The estimated 4-year EFS was 38% for the older group compared to 42% in the younger cohort (P=0.1). By multivariate analysis, the only factor found to influence survival in the older group was age-adjusted International Prognostic Index at relapse, 0–1 better than 2–3 (P=0.03). Autologous stem-cell transplant can be safely performed in patients 60 years or older with chemotherapy sensitive relapsed or first partial remission NHL. The outcome may not be different from that of younger patients in terms of TRM and EFS.